Dynavax Technologies (DVAX) Stock Price, News & Analysis

Company Overview

Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of novel vaccines and immunotherapies. Headquartered in Emeryville, California, the company specializes in leveraging its proprietary Toll-like receptor (TLR) agonist platform to enhance immune responses. Its lead product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration that incorporates the CpG 1018 adjuvant to stimulate a rapid and robust antibody response in adults.

Founded in 1993, Dynavax has built a pipeline that extends beyond hepatitis B to include candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and emerging infectious diseases. The company’s approach centers on pairing antigen constructs with adjuvant technologies designed to improve efficacy, durability and overall immunogenicity. In parallel, Dynavax is exploring immuno-oncology applications by investigating how its TLR agonists can synergize with checkpoint inhibitors and other cancer therapies.

Dynavax maintains a presence in North America and Europe, both through direct commercialization efforts and strategic partnerships. In addition to its Emeryville headquarters, the company operates research and development facilities in the United Kingdom and collaborates with global pharmaceutical firms to broaden the reach of its vaccine and adjuvant technologies. These alliances have enabled Dynavax to navigate regulatory requirements and facilitate supply chain distribution in multiple regions.

Under the leadership of President and Chief Executive Officer Tony Wood, who joined the company in 2017, Dynavax continues to advance its development programs and expand commercial opportunities. The company’s scientific team includes experts in immunology, infectious disease and vaccine manufacturing, supporting a disciplined approach to clinical research and regulatory strategy. As Dynavax progresses its pipeline through clinical milestones, it aims to address unmet medical needs in both prophylactic and therapeutic settings.

Key Stats

• Today's Range: $15.50 to $15.50
• 50-Day Range: $15.38 to $15.72
• 52-Week Range: $9.20 to $15.73
• Volume: N/A
• Average Volume: 2.20 million shs
• Market Capitalization: $1.82 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $32.00
• Consensus Rating: Hold

Company Calendar

• Last Earnings: 11/05/2025
• Today: 5/20/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:DVAX
• CIK: 1029142
• Web: www.dynavax.com
• Phone: (510) 848-5100
• Fax: 510-848-1327
• Employees: 350
• Year Founded: 1996

Price Target and Rating

• Average Price Target for Dynavax Technologies: $32.00
• High Price Target: $32.00
• Low Price Target: $32.00
• Potential Upside/Downside: +106.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.37)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 48.44
• P/E Growth: N/A
• Net Income: $27.31 million
• Net Margins: -13.13%
• Pretax Margin: -12.29%
• Return on Equity: 7.18%
• Return on Assets: 4.08%

Debt

• Debt-to-Equity Ratio: 0.41
• Current Ratio: 7.62
• Quick Ratio: 6.94

Sales & Book Value

• Annual Sales: $330.51 million
• Price / Sales: 5.51
• Cash Flow: $0.16 per share
• Price / Cash Flow: 97.88
• Book Value: $4.54 per share
• Price / Book: 3.41

Miscellaneous

• Outstanding Shares: 117,425,000
• Free Float: 113,926,000
• Market Cap: $1.82 billion
• Optionable: Optionable
• Beta: 0.97